1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Novo Nordisk A/S
  6. News
  7. Summary
    NOVO B   DK0060534915


Delayed Quote. Delayed Nasdaq Copenhagen - 05/20 10:59:42 am
761.3 DKK   +4.16%
05/20European ADRs Move Sharply Higher in Friday Trading
05/20NOVO NORDISK : Berenberg remains Neutral
05/16European ADRs Move Higher in Monday Trading
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novo Nordisk A/S – Share repurchase programme

01/10/2022 | 08:24am EDT

Bagsværd, Denmark, 10 January 2022 – On 5 November 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 3 February 2021.

Under the programme initiated 5 November 2021, Novo Nordisk will repurchase B shares for an amount up to DKK 3.7 billion in the period from 11 November 2021 to 1 February 2022.

Since the announcement 22 December 2021, the following transactions have been made:

 Number of
B shares
purchase price
value, DKK
Accumulated, last announcement2,909,544 2,126,697,543
3 January 2022110,000722.9779,526,779
4 January 2022110,000690.9175,999,885
5 January 2022110,000688.9975,788,576
6 January 2022110,000669.8473,682,907
7 January 2022115,000663.2776,275,503
Accumulated under the programme3,464,544 2,507,971,192

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

With the transactions stated above, Novo Nordisk owns a total of 31,654,276 B shares of DKK 0.20 as treasury shares, corresponding to 1.4% of the share capital. The total amount of A and B shares in the company is 2,310,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 20 billion during a 12-month period beginning 3 February 2021. As of 7 January 2022, Novo Nordisk has since 3 February 2021 repurchased a total of 32,900,725 B shares at an average share price of DKK 571.52 per B share equal to a transaction value of DKK 18,803,497,636.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 47,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, and YouTube.

Further information

Mette Kruse Danielsen+45 3079 3883mkd@novonordisk.com
Michael Bachner (US)+1 609 664 7308mzyb@novonordisk.com
Daniel Muusmann Bohsen+45 3075 2175dabo@novonordisk.com
Ann Søndermølle Rendbæk+45 3075 2253arnd@novonordisk.com
David Heiberg Landsted+45 3077 6915dhel@novonordisk.com
Mark Joseph Root (US)+1 848 213 3219mjhr@novonordisk.com

Company announcement No 1 / 2022


  • CA220110_Share_repurchase

© OMX, source GlobeNewswire - EU Press Releases

All news about NOVO NORDISK A/S
05/20European ADRs Move Sharply Higher in Friday Trading
05/20NOVO NORDISK : Berenberg remains Neutral
05/16European ADRs Move Higher in Monday Trading
05/16NOVO NORDISK A/S : Share repurchase programme
05/16NOVO NORDISK A/S : Share repurchase programme
05/13U.S. FDA approves Eli Lilly's treatment for type 2 diabetes
05/12NOVO NORDISK : Barclays gives a Buy rating
05/11NOVO NORDISK A/S : Trading in Novo Nordisk shares by board members, executives and associa..
05/11NOVO NORDISK : Deutsche Bank keeps its Buy rating
05/10Novo Nordisk Starts Research Collaboration With Flagship Pioneering
More news
Analyst Recommendations on NOVO NORDISK A/S
More recommendations
Sales 2022 166 B 23 554 M 23 554 M
Net income 2022 52 875 M 7 494 M 7 494 M
Net cash 2022 4 087 M 579 M 579 M
P/E ratio 2022 32,4x
Yield 2022 1,51%
Capitalization 1 729 B 245 B 245 B
EV / Sales 2022 10,4x
EV / Sales 2023 9,16x
Nbr of Employees 49 295
Free-Float 69,6%
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | NOVO B | DK0060534915 | MarketScreener
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 761,30 DKK
Average target price 791,88 DKK
Spread / Average Target 4,02%
EPS Revisions
Managers and Directors
Lars Fruergaard J°rgensen President & Chief Executive Officer
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Helge Lund Chairman
Henrik Ehlers Wulff Senior Vice President-Diabetes API
Stephen Gough Global Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVO NORDISK A/S3.58%245 099
JOHNSON & JOHNSON1.68%465 705
PFIZER, INC.-11.14%294 404
ABBVIE INC.11.53%266 851
ROCHE HOLDING AG-15.67%266 707